Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for JNJ.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 1996. Start Trial.
Date Value
June 30, 2026 -1.11B
March 31, 2026 -1.04B
December 31, 2025 -4.485B
September 30, 2025 -542.00M
June 30, 2025 -18.26B
March 31, 2025 -297.00M
December 31, 2024 -1.32B
September 30, 2024 -3.128B
June 30, 2024 -13.69B
March 31, 2024 -464.00M
December 31, 2023 -1.202B
September 30, 2023 2.541B
June 30, 2023 -3.776B
March 31, 2023 3.315B
December 31, 2022 -4.397B
September 30, 2022 -1.701B
June 30, 2022 -2.639B
March 31, 2022 -3.634B
December 31, 2021 -5.36B
September 30, 2021 -2.719B
June 30, 2021 -419.00M
March 31, 2021 -185.00M
December 31, 2020 -7.903B
September 30, 2020 -4.819B
June 30, 2020 -7.522B
Date Value
March 31, 2020 -581.00M
December 31, 2019 -1.344B
September 30, 2019 -1.645B
June 30, 2019 -1.788B
March 31, 2019 -1.417B
December 31, 2018 2.228B
September 30, 2018 -4.269B
June 30, 2018 -201.00M
March 31, 2018 -925.00M
December 31, 2017 -505.00M
September 30, 2017 -1.18B
June 30, 2017 -12.25B
March 31, 2017 -936.00M
December 31, 2016 -2.174B
September 30, 2016 -2.372B
June 30, 2016 1.322B
March 31, 2016 -1.537B
December 31, 2015 -1.391B
September 30, 2015 -1.001B
June 30, 2015 -3.554B
March 31, 2015 -1.789B
December 31, 2014 -2.922B
September 30, 2014 735.00M
June 30, 2014 -8.092B
March 31, 2014 -2.026B

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Eli Lilly & Co. -15.40B
Merck & Co., Inc. -5.602B
Pfizer Inc. 2.106B
Bristol Myers Squibb Co. -1.614B
Liquidia Corp. -12.24M